CellPro correction
This article was originally published in The Gray Sheet
Executive Summary
Bothell, Washington-based CellPro will initiate Phase III trials of the tumor purging effect of the company's Ceprate stem cell concentration system in patients with multiple myeloma. The patient population was incorrectly reported in "The Gray Sheet" (Nov. 7, I&W-25)